Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Feneberg

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
European Biophysics Journal : EBJ|September 8, 2001
Dictyostelium cells' cytoplasm as an active viscoplastic bodyW Feneberg, M Westphal, E Sackmann
Der Nervenarzt|February 11, 2004
[Pain in multiple sclerosis--a still underestimated problem. The 1 year prevalence of pain syndromes, significance and quality of care of multiple sclerosis inpatients]W Pöllmann, W Feneberg, L-P Erasmus
Fortschritte Der Neurologie-Psychiatrie|May 10, 2005
[Therapy of pain syndromes in multiple sclerosis -- an overview with evidence-based recommendations]W Pöllmann, W Feneberg, A Steinbrecher, et al.
Neurology|August 28, 2002
Interferon beta but not glatiramer acetate therapy aggravates headaches in MSW Pöllmann, L-P Erasmus, W Feneberg, et al.
Neuroscience Letters|May 18, 2001
No association between anti-myelin oligodendrocyte glycoprotein antibodies and serum/cerebrospinal fluid levels of the soluble interleukin-6 receptor complex in multiple sclerosisF Padberg, C G Haase, W Feneberg, et al.
Neurology|February 22, 2008
TNFRSF1A R92Q mutation in association with a multiple sclerosis-like demyelinating syndromeL A Hoffmann, P Lohse, F B König, et al.
Der Nervenarzt|October 29, 2017
[New aspects of symptomatic MS treatment: Part 5 - fatigue]T Henze, W Feneberg, P Flachenecker, et al.
Der Nervenarzt|October 25, 2017
[What is new in symptomatic MS treatment: Part 2-gait disorder and spasticity]T Henze, W Feneberg, P Flachenecker, et al.
Der Nervenarzt|October 25, 2017
[What is new in symptomatic MS treatment: Part 1-introduction and methodical approach, ataxia and tremor]T Henze, W Feneberg, P Flachenecker, et al.
Neurology|November 26, 2008
Multiple sclerosis and the TNFRSF1A R92Q mutation: clinical characteristics of 21 casesT Kümpfel, L-A Hoffmann, H Pellkofer, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
European Biophysics Journal : EBJ|September 8, 2001
Dictyostelium cells' cytoplasm as an active viscoplastic bodyW Feneberg, M Westphal, E Sackmann
Der Nervenarzt|February 11, 2004
[Pain in multiple sclerosis--a still underestimated problem. The 1 year prevalence of pain syndromes, significance and quality of care of multiple sclerosis inpatients]W Pöllmann, W Feneberg, L-P Erasmus
Fortschritte Der Neurologie-Psychiatrie|May 10, 2005
[Therapy of pain syndromes in multiple sclerosis -- an overview with evidence-based recommendations]W Pöllmann, W Feneberg, A Steinbrecher, et al.
Neurology|August 28, 2002
Interferon beta but not glatiramer acetate therapy aggravates headaches in MSW Pöllmann, L-P Erasmus, W Feneberg, et al.
Neuroscience Letters|May 18, 2001
No association between anti-myelin oligodendrocyte glycoprotein antibodies and serum/cerebrospinal fluid levels of the soluble interleukin-6 receptor complex in multiple sclerosisF Padberg, C G Haase, W Feneberg, et al.
Neurology|February 22, 2008
TNFRSF1A R92Q mutation in association with a multiple sclerosis-like demyelinating syndromeL A Hoffmann, P Lohse, F B König, et al.
Der Nervenarzt|October 29, 2017
[New aspects of symptomatic MS treatment: Part 5 - fatigue]T Henze, W Feneberg, P Flachenecker, et al.
Der Nervenarzt|October 25, 2017
[What is new in symptomatic MS treatment: Part 2-gait disorder and spasticity]T Henze, W Feneberg, P Flachenecker, et al.
Der Nervenarzt|October 25, 2017
[What is new in symptomatic MS treatment: Part 1-introduction and methodical approach, ataxia and tremor]T Henze, W Feneberg, P Flachenecker, et al.
Neurology|November 26, 2008
Multiple sclerosis and the TNFRSF1A R92Q mutation: clinical characteristics of 21 casesT Kümpfel, L-A Hoffmann, H Pellkofer, et al.
Pageof 2